Journal of Diabetes and Its Complications
Volume 25, Issue 3 , Pages 143-150 , May 2011

Impact of thiazolidinedione safety warnings on medication use patterns and glycemic control among veterans with diabetes mellitus

  • Lizheng Shi

      Affiliations

    • School of Public Health and Tropical Medicine, Tulane University
    • School of Medicine, Tulane University
    • Southeast Louisiana Veterans Health Care System
    • Corresponding Author InformationCorresponding author. School of Public Health and Tropical Medicine, 1440 Canal Street, Suite 1900, Tulane University, New Orleans, LA 70112. Tel.: +1 504 988 6548.
    • ,
  • Yingnan Zhao

      Affiliations

    • School of Public Health and Tropical Medicine, Tulane University
    • Southeast Louisiana Veterans Health Care System
    • ,
  • Keith Szymanski

      Affiliations

    • Takeda Pharmaceuticals America, USA
    • ,
  • Lillian Yau

      Affiliations

    • School of Public Health and Tropical Medicine, Tulane University
    • Southeast Louisiana Veterans Health Care System
    • ,
  • Vivian Fonseca

      Affiliations

    • School of Medicine, Tulane University
    • Southeast Louisiana Veterans Health Care System

Received 23 February 2010 ,Revised 9 May 2010 ,Accepted 23 June 2010.

References 

  1. American Diabetes Association . Standards of medical care in diabetes—2008. [see comment] Diabetes Care. 2008;31(Suppl 1):S12–S54
  2. Anonymous . U.S. Food and Drug Administration Center for Drug Evaluation and Research. Summary minutes of the joint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. 2007;
  3. Deeg MA, Buse JB, et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2007;30(10):2458–2464
  4. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events): a randomised controlled trial. Lancet. 2005;366:1279–1289
  5. FDA . Information for healthcare professionals. Rosiglitazone maleate (marketed as Avandia, Avandamet, and Avandaryl). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm143406.htm2007;
  6. FDA News . Manufacturers of some diabetes drugs to strengthen warning on heart failure risk. 2007;www.fda.gov/bbs/topics/NEWS/2007/NEW01683.html
  7. FDA News . FDA issues safety alert on Avandia. 2009;www.fda.gov/bbs/topics/NEWS/2007/NEW01636.html
  8. Fonseca, V. A. (2007). Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus.
  9. Ford ES, Li C, et al. Trends in A1C concentrations among U.S. adults with diagnosed diabetes from 1999 to 2004.. Diabetes Care. 2008;31(1):102–104
  10. Grundy SM, Brewer HB, et al. National Heart, Lung, and Blood Institute: definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109(3):433–438
  11. Home PD, Pocock SJ, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125–2135
  12. Kahn SE, Haffner SM, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. New England Journal of Medicine. 2006;355(23):2427–2443
  13. Nathan DM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes association and the European Association for the Study of Diabetes. Diabetes Care. 2008;31:173–175
  14. Nathan DM, Buse JB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203
  15. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New England Journal of Medicine. 2007;356(24):2457
  16. O'Connor PJ, Rush WA, et al. Identifying diabetes mellitus or heart disease among health maintenance organization members: sensitivity, specificity, predictive value, and cost of survey and database method. American Journal of Managed Care. 1998;4:335–342
  17. Shah BR, Juurlink DN, et al. New use of rosiglitazone decreased following publication of a meta-analysis suggesting harm. Diabetic Medicine. 2008;25(7):871–874
  18. Starner CI, Schafer JA, et al. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. Journal of Managed Care Pharmacy. 2008;14(6):523–531
  19. Zhu SK, Wang ZM, et al. Waist circumference and obesity-associated risk factors among whites in the third National Health and Nutrition Examination Survey: clinical action thresholds. American Journal of Clinical Nutrition. 2002;76(4):743–749

☆ Shi, Yau, Fonseca, and Zhao are also WOC employees/investigators for the Southeast Louisiana Veterans Health Care System. Shi has received research support (to Tulane) from Eli Lilly, Takeda, and Blue Cross Blue Shield of Louisiana. Fonseca has received research support (to Tulane) from GlaxoSmithKline, Novartis, Novo-Nordisk, Takeda, Astra-Zeneca, Pfizer, Sanofi- Aventis, Eli Lilly, Daiichi-Sankyo, National Institutes of Health, and the American Diabetes Association; Fonseca has also received honoraria for consulting and lectures from GlaxoSmithKline, Novartis, Takeda, Novo-Nordisk, Sanofi- Aventis, Eli Lilly, and Daiichi Sankyo. Fonseca is currently the chair of a data monitoring committee for a clinical trial sponsored by Takeda. Dr. Keith Szymanski is a clinical science and outcomes manager in the medical affairs division of Takeda Pharmaceuticals North America, Inc.

☆☆ Data analysis was performed primarily by Ms. Zhao, and data interpretation was performed by all authors. Drs. Shi and Fonseca wrote the manuscript with assistance from Dr. Szymanski. All authors contributed to the revisions of the manuscript.

PII: S1056-8727(10)00068-1

doi: 10.1016/j.jdiacomp.2010.06.003

Journal of Diabetes and Its Complications
Volume 25, Issue 3 , Pages 143-150 , May 2011

Article Tools

* Image Usage & Resolution